Key result
CDK9 promotes neointima formation after vascular injury by targeting Twist1.
Why the study?
Restenosis limits percutaneous coronary intervention via vascular smooth muscle cell proliferation, migration, and phenotypic switching, and whether and how cyclin-dependent kinase 9 (CDK9) regulates vascular remodeling after injury remained to be investigated.
Does CDK9 inhibition or overexpression regulate neointimal formation and VSMC phenotypic switching, proliferation, and migration in C57BL/6J mice undergoing carotid artery ligation and cultured VSMCs?
Does CDK9 inhibition or overexpression regulate neointimal formation and VSMC phenotypic switching, proliferation, and migration in C57BL/6J mice undergoing carotid artery ligation and cultured VSMCs?
Inhibition of CDK9 ameliorates vascular injury-induced neointimal hyperplasia and suppresses VSMC proliferation, migration, and phenotypic switching by directly targeting the transcription factor Twist1 in preclinical models.
Answers are grounded in this paper and cite their sources.
May identify CDK9-Twist1 inhibition for restenosis prevention; leaves open translation to human trials.
Restenosis is a major limiting factor of percutaneous coronary intervention, accompanied by abnormal proliferation, migration and phenotypic switching of vascular smooth muscle cells (VSMCs). As a key component of the positive transcription elongation factor b complex, cyclin‑dependent kinase 9 (CDK9) phosphorylates RNA polymerase II (RNA Pol II) and regulates various genes that are involved in the regulation of diverse cellular processes, including cell proliferation. The present study aimed to investigate whether and how CDK9 regulates vascular remodeling after injury in mice. Carotid artery ligation was performed in C57BL/6J mice, and cultured VSMCs were treated with platelet‑derived growth factor‑BB, iCDK9, Thal‑SNS‑032, harmine or CDK9‑overexpressing recombinant adenovirus. Neointimal formation, proliferation, migration and phenotypic switching were examined by histological quantification, western blotting, reverse transcription‑quantitative PCR, 5‑ethynyl‑2'‑deoxyuridine incorporation, wound‑healing and immunofluorescence assays, and the mechanism was explored by RNA‑sequencing, chromatin immunoprecipitation and luciferase reporter assays. The results revealed a notable upregulation of CDK9 and the phosphorylation of RNA Pol II at Ser2 in VSMCs during neointimal hyperplasia following carotid artery injury, and the neointimal formation could be markedly ameliorated by a CDK9 inhibitor. Furthermore, overexpression of CDK9 promoted the phenotypic switching, proliferation and migration of VSMCs in vitro, whereas inhibition of CDK9 produced the opposite results. Furthermore, CDK9 exerted its biological function by directly targeting the transcription factor Twist1, which is a key inducer of epithelial‑mesenchymal transition that has been widely implicated in the pathological progression of cardiovascular diseases. Additionally, application of the Twist1 inhibitor harmine markedly abolished the function of CDK9 in promoting the phenotypic switching, proliferation and migration of VSMCs in vitro. In conclusion, the present study explored the function of CDK9 in vascular injury‑induced neointimal hyperplasia and established that CDK9 may exert direct targeting regulation on the transcription factor Twist1 within this pathological cascade.
No takes yet. Share an insight, caveat, or question.
余立清 et al. (2026) studied Neointima formation following vascular injury. CDK9 was evaluated on Neointima formation. CDK9 regulates neointima formation following vascular injury by targeting the transcription factor Twist1, though quantitative study text was omitted.
Synapse has enriched 10 related papers. Consider them for comparative context: